full free access: Personalized Medicine and Cancer Supportive Care: Appropriate Use of Colony-Stimulating Factor Support of Chemotherapy Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, June 22, 2011

full free access: Personalized Medicine and Cancer Supportive Care: Appropriate Use of Colony-Stimulating Factor Support of Chemotherapy



"Unfortunately, patients in RCTs (randomized clinical trials) are often highly selected, and toxicities, including FN, are frequently underreported (18). In addition, chemotherapy dose intensity and the use of prophylactic CSF or antibiotics are infrequently reported in RCTs, making it difficult to assess the true burden of neutropenic complications associated with a chemotherapy regimen (18)." "....Although there is little debate that both underuse and overuse of the CSFs occur in clinical practice, accurate estimates of the true magnitude and impact of such considerations remain elusive. What is clear is that there is a need for greater attention to chemotherapy-associated toxicities along with accurate prediction tools for the assessment of individual patient risks, including FN (febrile neutropenia) and its complications. Such tools could improve the evidence base for practice guidelines and aid clinicians in the selection of patients with cancer who are at an individual increased risk for FN, and therefore, appropriate candidates for the clinically effective and cost-effective use of the CSFs (40)."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.